Showing results (331-340 of 376) with videos related to

Sort By:
Pageof 38
Clinical Genitourinary Cancer|January 19, 2016
Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer CenterVinayak Muralidhar, Meredith M Regan, Lillian Werner, et al.
World Journal of Urology|January 20, 2024
The effect of limited english proficiency on prostate-specific antigen screening in American menBenjamin V Stone, Muhieddine Labban, Edoardo Beatrici, et al.
The Lancet. Oncology|December 11, 2012
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort studyFabio A B Schutz, Mark M Pomerantz, Kathryn P Gray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and CrizotinibAbhishek Tripathi, Jeffrey G Supko, Kathryn P Gray, et al.
Nature Genetics|October 13, 2015
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesisMark M Pomerantz, Fugen Li, David Y Takeda, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2010
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYCNasim Ahmadiyeh, Mark M Pomerantz, Chiara Grisanzio, et al.
Frontline Gastroenterology|March 15, 2024
Tailoring follow-up endoscopy in patients with severe oesophagitisRebecca K Grant, William M Brindle, Caitlyn L Taylor, et al.
Ecology|December 3, 2016
Coast-wide recruitment dynamics of Olympia oysters reveal limited synchrony and multiple predictors of failureKerstin Wasson, Brent B Hughes, John S Berriman, et al.
Cancer|June 14, 2017
The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancerMark M Pomerantz, Sandor Spisák, Li Jia, et al.
JCO Precision Oncology|September 14, 2022
Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate CancerJacob E Berchuck, Daniel Boiarsky, Rebecca Silver, et al.
Pageof 38